Recruiting
Phase 1

VTC-G15

Sponsor:

Elahi, Dariush, PhD

Code:

NCT02518932

Conditions

Insulin Resistance

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Last 5 amino acids of GLP-1

placebo saline

Study Details

Brief summary:

To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.

Conditions

Insulin Resistance

Study ID

NCT02518932

Start date

Mar, 2015

Status verified date

Aug, 2015

Completion date

Mar, 2016

Anticipated

Primary completion date

Mar, 2016

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • BMI 18.5-25;
  • 33-38

Exclusion Criteria:

  • T2D
  • T1D
  • Hypoglycemic agents

Study Design

Enrollment

20 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Drug GLP-1 (32-36) Amide

To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp

placebo comparator: Placebo

To examine the effect of saline on glucose uptake

Interventions

Last 5 amino acids of GLP-1

To examine insulinomimetic properties of LVKGR

placebo saline

Primary outcome measure

  • The effect of VTC-G15 on whole body glucose metabolism in man will be assessed by comparison of amont of glucose infusion during the peptide infusion compared to amount of infusion during placebo infusion (saline) mg/kg/min. [ Time Frame: one year ]

Central Contacts and Locations

Central contacts

Dariush E;ahi, PhD

210-283-4520dariush.elahi@iconplc.com

Dennis A Ruff, MD

210-283-4572dennis.ruff@iconplc.com

Locations

ICON PLC

Recruiting

San Antonio, Texas, United States, 78209

Contacts

Rita Flusche

210-283-4123Rita.flusche@iconplc.com

More Information

Sponsor

Elahi, Dariush, PhD

Last update posted

Aug 10, 2015

Last verified

Aug, 2015

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Elahi, Dariush, PhD on 2015-08-10.